STAAR Surgical Nearing Inflection Point for Full China Rebound, Wedbush Says

MT Newswires Live05-14

STAAR Surgical (STAA) is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.

The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.

Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.

Analysts said the company reported "strong" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.

The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high season during Q2 and Q3, according to the note.

Wedbush raised STAAR Surgical's 2026 revenue estimate to $350.1 million from $320.2 million. Analysts polled by FactSet expect $326.1 million.

The firm upgraded the stock's rating to outperform from neutral, and raised its price target to $40 from $26.

Price: 33.36, Change: +3.96, Percent Change: +13.48

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635174626?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 22:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635174626","market":"nz","top_or_hot":-1,"title":"STAAR Surgical Nearing Inflection Point for Full China Rebound, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical</a> (STAA) is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.</p><p>The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.</p><p>Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.</p><p>Analysts said the company reported \"strong\" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.</p><p>The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high season during Q2 and Q3, according to the note.</p><p>Wedbush raised STAAR Surgical's 2026 revenue estimate to $350.1 million from $320.2 million. Analysts polled by FactSet expect $326.1 million.</p><p>The firm upgraded the stock's rating to outperform from neutral, and raised its price target to $40 from $26.</p><p>Price: 33.36, Change: +3.96, Percent Change: +13.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>STAAR Surgical Nearing Inflection Point for Full China Rebound, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSTAAR Surgical Nearing Inflection Point for Full China Rebound, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-14 22:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/STAA\">STAAR Surgical</a> (STAA) is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.</p><p>The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.</p><p>Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.</p><p>Analysts said the company reported \"strong\" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.</p><p>The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high season during Q2 and Q3, according to the note.</p><p>Wedbush raised STAAR Surgical's 2026 revenue estimate to $350.1 million from $320.2 million. Analysts polled by FactSet expect $326.1 million.</p><p>The firm upgraded the stock's rating to outperform from neutral, and raised its price target to $40 from $26.</p><p>Price: 33.36, Change: +3.96, Percent Change: +13.48</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635174626","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635174626","pubTimestamp":1778770692,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"STAAR Surgical  is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.Analysts said the company reported \"strong\" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high seas","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","BK4588":"碎股","BK4585":"ETF&股票定投概念","STAA":"STAAR Surgical Company","BK4548":"巴美列捷福持仓"},"translate_title":"韦德布什表示，STAAR Surgical已接近中国全面反弹的拐点","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":1},"content_text":"STAAR Surgical (STAA) is already at or is nearing an inflection point for a full China rebound, Wedbush Securities said in a Thursday note.The brokerage said the company has the potential to exceed even their bull-case scenario in the coming quarters and further incremental recovery in China will likely lead to a re-rating of its valuation.Wedbush said STAAR's dominant market position in phakic intraocular lenses, continued growth outside China and favorable long-term industry dynamics provide multiple paths to value creation.Analysts said the company reported \"strong\" Q1 results, beating both Wedbush's raised estimates and consensus expectations. Results were driven by a stronger-than-expected recovery in China and continued double-digit US growth.The distributor inventory levels in China remained at or below contractual targets, suggesting revenue was driven by genuine market demand rather than channel restocking. The company could benefit from seasonal strength in China's summer high season during Q2 and Q3, according to the note.Wedbush raised STAAR Surgical's 2026 revenue estimate to $350.1 million from $320.2 million. Analysts polled by FactSet expect $326.1 million.The firm upgraded the stock's rating to outperform from neutral, and raised its price target to $40 from $26.Price: 33.36, Change: +3.96, Percent Change: +13.48","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635174626","isCrawlerRequest":true}